REACH2: ruxolitinib for refractory aGvHD

Nature Reviews Clinical Oncology, Published online: 06 May 2020; doi:10.1038/s41571-020-0385-zREACH2: ruxolitinib for refractory aGvHD

Source: Nature Reviews Clinical Oncology - May 5, 2020 Category: Cancer & Oncology Authors: David Killock Source Type: research